Newsroom: Latest News
Igyxos selected for the French Tech 120 (FT120) program for the third consecutive year
Nouzilly, April 25, 2022 – Igyxos, a biotechnology company specializing in the treatment of female and male infertility, is pleased to announce that it has been selected for the third consecutive year for the French Tech 120 (FT120) program. The French Tech 120 list represents the 120 top performing and rapidly growing startups based in France across all industries, including 7 biotechnology companies developing innovative therapies. The goal of the FTE120 program is to promote the growth of French technological leaders with worldwide reach by providing increased visibility, and specific services (financing, international development, recruitment, etc…).
“We are honored to be recognized in the French Tech 120 program. Last year was transformative for Igyxos as we entered into preclinical development of our innovative product, IGX12” said Pierre-Henry Longeray, Igyxos’ Chief Executive Officer. “We look forward to pursuing the development of IGX12 to improve fertility and to leveraging the French Tech 120 program and recognition.”
About French Tech 120
The objective of the French Tech 120 is to support the development of these new technological players that respond to the major challenges facing society: offering solutions for the ecological transition, for the health of citizens, for mobility, to modernize the fabric of SMEs and ETIs, etc. The French Tech 120 offers support designed for French scale-ups capable of becoming world-class technology leaders. 120 French start-ups and scale-ups are selected each year to be part of the program. The selection, based on financial criteria of fundraising or hypergrowth of sales, is open to all models of startups (digital, deeptech, industrial) and all sectors of activity.
Igyxos’ mission is to develop new and innovative medical and pharmaceutical technologies in the field of human fertility. Igyxos is involved in all phases of development, from the discovery of promising targets to the identification of potential active compounds such as antibodies. The success of its €7.5 million Series A funding led by Bpifrance, through the FABS funds, alongside with Go Capital Amorçage II and Loire Valley Invest Funds managed by Go Capital and the Emergence Innovation II Fund managed by Sofimac Innovation, will allow Igyxos to develop its lead compound and reach clinical proof of concept. www.igyxos.com.
06 64 28 81 31
06 03 34 75 36